BioSight
Companies
PUMA BIOTECHNOLOGY, INC. logo

PBYI

NASDAQLOS ANGELES, CA
PUMA BIOTECHNOLOGY, INC.

PUMA Biotechnology develops and commercializes drugs for cancer treatment, with a focus on breast cancer and HER2-targeted therapies. The company's lead product, NERLYNX (neratinib), is a commercialized tablet treatment, while additional drug candidates are in clinical development stages. PUMA also works with sub-licensees to obtain regulatory approval and commercialize products outside the United States.

Price history not yet available for PBYI.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar